Categories: HealthcareNews

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.

To attend the virtual fireside chat, please register here. In addition, the MediWound management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid®, is FDA and EMA-approved as an orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Building on its proprietary enzymatic platform, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. With distinct advantages over the current $360+ million market leader, EscharEx offers a unique opportunity for significant market expansion.

For more information visit www.mediwound.com and follow us on LinkedIn.

   
MediWound Contacts:  
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com  daniel@lifesciadvisors.com 
   
Media Contact:  
Ellie Hanson  
FINN Partners for MediWound  
ellie.hanson@finnpartners.com   
+1-929-588-2008  
   

Staff

Recent Posts

Ascentiz Unveiled Modular Designed Exoskeleton at CES 2026: A Technical Deep Dive into Biomechanical Intelligence

The world's first modular exoskeleton combines quasi-direct-drive hip and cable-drive knee technologies for natural, powerful…

5 hours ago

From Clinical Recovery to Lifelong Empowerment: RoboCT Showcases Integrated Ecosystem Strategy at CES 2026

Leveraging Medical Robotics Heritage, the Company Expands into Consumer Market, Envisioning Exoskeletons as Integral 'New…

5 hours ago

Nanodropper® Now Operating as Mu Medical™, Planned Expansion of Precision Eyecare Platform with Bedo Solutions and Viseon Labs

The consolidated entity will leverage AI and precision engineering to create a comprehensive ecosystem advancing…

5 hours ago

Flo Health’s App Wins Google Play “Best of 2025” Award for Best for Watches in Hong Kong, Taiwan, and Macau

LONDON, Jan. 9, 2026 /PRNewswire/ -- Flo Health, the company behind the globally trusted Flo…

5 hours ago

Gifthealth Celebrates Grand Opening Of New Pharmacy In Mesa

MESA, Ariz., Jan. 9, 2026 /PRNewswire/ -- Gifthealth, a unified digital pharmacy platform, today celebrated the…

5 hours ago

Lucent Health Names Aadam Hussain as Chief Executive Officer Following Brett Rodewald’s Retirement

NASHVILLE, Tenn., Jan. 9, 2026 /PRNewswire/ -- Today, Lucent Health, one of the nation's largest independent…

5 hours ago